Evidence map›Paper›PMID 30180158›Full record

ArticlePloS one2018

Label-free toxicology screening of primary human mesenchymal cells and iPS-derived neurons.

Maria Serena Piccinno, Tiziana Petrachi, Elisa Resca, Valentina Strusi, Valentina Bergamini, Giuseppe Antonio Mulas, Giorgio Mari, Massimo Dominici, Elena Veronesi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Maria Serena PiccinnoScience & Technology Park for Medicine (TPM), Mirandola, Italy.
Tiziana PetrachiScience & Technology Park for Medicine (TPM), Mirandola, Italy.
Elisa RescaScience & Technology Park for Medicine (TPM), Mirandola, Italy.
Valentina StrusiScience & Technology Park for Medicine (TPM), Mirandola, Italy.
Valentina BergaminiDepartment of Medical and Surgical Sciences for Children & Adults, University-Hospital of Modena and Reggio Emilia, Modena, Italy.
Giuseppe Antonio MulasScience & Technology Park for Medicine (TPM), Mirandola, Italy.
Giorgio MariScience & Technology Park for Medicine (TPM), Mirandola, Italy.
Massimo DominiciScience & Technology Park for Medicine (TPM), Mirandola, Italy.
Elena VeronesiScience & Technology Park for Medicine (TPM), Mirandola, Italy.ORCID 0000-0001-6262-1388
University of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high-throughput, label-free Corning Epic assay has applications in drug discovery, pharmacogenomics, cell receptor signaling, cell migration, and viral titration. The utility of Epic technology for biocompatibility testing has not been well established. In manufacturing of medical devices, in vitro and in vivo biocompatibility assessments are mandatory, according to ISO 10993. The new medical device regulation MDR 745/2017 specifies that ex vivo assays that can closely recapitulate in vivo scenarios are needed to better evaluate biomedical devices. We propose herein that Epic technology-which enables detection of variations in cell mass distribution-is suitable for biocompatibility screening of compounds. In this study, we challenged primary human osteoblasts, endothelial cells, and neurons derived from induced pluripotent stem cells with specific concentrations of methyl methacrylate (MMA). Polymeric MMA has long been applied in cranioplasty, where it makes contact with multiple cell types. Application of Epic technology yielded real-time cytotoxicity profiles for all considered cell types. The results were compared with those from microscopic observation of the same culture plate used in the Epic analyses. The Epic assay should be further examined for its utility for cell biology, genomics, and proteomics companion assays. Our results suggest that Epic technology can be applied to biocompatibility evaluation of human cells in medical device development.

Indexed as

Cell DifferentiationDrug Evaluation, PreclinicalHumansInduced Pluripotent Stem CellsMesenchymal Stem CellsMethylmethacrylateNeuronsPrimary Cell CultureMethylmethacrylate

Identifiers

PMID30180158
PMCPMC6122932
OpenAlexW2889995803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.